Who are SUBLIVAC® Grasses treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PURETHAL Grasses, 20.000 AUM/ml, ragweed pollen, wasp venom, Staloral TM, House dust mite Novo Helisen Depot, tree 12 SQ-Bet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sublivac-grasses-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

SUBLIVAC® Grasses treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SUBLIVAC® Grasses treatment (SUBLIVAC® Grasses treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology.

phase 3 Allergen immunotherapy Immunology Small molecule Live · refreshed every 30 min

Target snapshot

SUBLIVAC® Grasses treatment (SUBLIVAC® Grasses treatment) — HAL Allergy. SUBLIVAC Grasses treatment works by desensitizing patients to grass allergens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SUBLIVAC® Grasses treatment TARGET	SUBLIVAC® Grasses treatment	HAL Allergy	phase 3	Allergen immunotherapy
PURETHAL Grasses, 20.000 AUM/ml	PURETHAL Grasses, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Grass pollen allergens (IgE and T-cell epitopes)
ragweed pollen	ragweed pollen	The University of Texas Medical Branch, Galveston	marketed	Allergen immunotherapy
wasp venom	wasp venom	Allergopharma GmbH & Co. KG	marketed	Allergen immunotherapy
Staloral TM	Staloral TM	National Taiwan University Hospital	marketed	Allergen immunotherapy
House dust mite Novo Helisen Depot	House dust mite Novo Helisen Depot	Allergopharma GmbH & Co. KG	marketed	Allergen immunotherapy
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SUBLIVAC® Grasses treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/sublivac-grasses-treatment. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab